| Systematic (IUPAC) name | |
|---|---|
| (6aR,9R)- N,N- diallyl- 7-methyl- 4,6,6a,7,8,9- hexahydroindolo- [4,3-fg] quinoline- 9- carboxamide | |
| Identifiers | |
| CAS number | ? |
| ATC code | none |
| PubChem | ? |
| Chemical data | |
| Formula | C22H25N3O |
| Mol. mass | 349.467 g/mol |
| Synonyms | DAL, Lysergic acid diallylamide, d-lysergic acid diallylamide, d-diallyllysergamide |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | hepatic |
| Half life | ? |
| Excretion | renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Controlled in the US via the Federal Analog Act |
| Routes | Oral
|
Diallyllysergamide (DAL, as the tartrate salt) is a psychedelic lysergamide. In their book TiHKAL, Alexander and Ann Shulgin describe it as being "an order of magnitude less potent than LSD itself".
| This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)




